Defensin-antigen fusion proteins

Details Defensin-antigen fusion proteins Defensin-antigen fusion proteins

2011-02-01

2011-12-27

Carlson, Karen (Department: 1656)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023100, C514S001000, C530S350000

Reexamination Certificate

active

08084250

ABSTRACT:
The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4704362 (1987-11-01), Itakura et al.
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6001649 (1999-12-01), Caput et al.
patent: 6562347 (2003-05-01), Kwak et al.
patent: 2003/0138452 (2003-07-01), Kwak et al.
patent: 2004/0110165 (2004-06-01), Kwak et al.
patent: 0706799 (1996-04-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 97/35008 (1997-09-01), None
patent: WO 98/01564 (1998-01-01), None
patent: WO 98/07833 (1998-02-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 00/78334 (2000-12-01), None
International Search Report from prior PCT Application No. PCT/US2001/029074, 5 pp, (mailed Jul. 29, 2002).
Lofthouse et al., “Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumor antigen,”Vaccine15(14): 1586-1593 (1997).
Biragyn et al. “E. coliExpressed Lymphoma IG Idiotype Antigen Fusion Proteins and Chimeric, HBcAG Particles Bearing Tumor Epitopes”Cancer Biotherapy10(1):85 (Mar. 3, 1995).
Boon, “Toward a genetic analysis of tumor rejection antigens,”Advances in Cancer Res.58:177-210, 1992.
Cocchi et al. “The V3 Domain of the HIV-1 gp120 Envelope Glycoprotein Is Critical for Chemokine-Mediated Blockade of Infection”Nature Medicine2(11):1244-7 (Nov. 1996).
Hellstrom et al, “Can co-stimulated tumor immunity be therapeutically efficacious?”Immunol. Rev.145:123-145(1995).
Kwak et al. “Idiotypes as Vaccines for the Treatment of B-Cell Malignancies”Immunotechnology2(4):268 (Nov. 1, 1996).
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Preliminary Amendment, Mar. 12, 2000.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Restriction Requirement, Jan. 10, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Restriction Requirement, Feb. 2, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Restriction Requirement, Mar. 2, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Non-final Office Action, May 11, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Non-Final Office Action, Sep. 12, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Final Office Action, Nov. 30, 2001.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Final Office Action, Apr. 1, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Advisory Action, Apr. 25, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Advisory Action and Request for Continued Examination, Apr. 30, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Final Office Action Jul. 3, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Final Office Action, Oct. 30, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Advisory Action, Nov. 12, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Response to Advisory Action, Dec. 3, 2002.
U.S. Appl. No. 09/646,028, Kwak et al., filed Mar. 12, 1999, Notice of Allowance, Dec. 19, 2002.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Preliminary Amendment, Dec. 31, 2002.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Restriction Requirement, Feb. 10, 2005.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Response to Restriction Requirement, Apr. 11, 2005.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Non-final Office Action, Jun. 7, 2005.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Response to Non-final Office Action, Dec. 7, 2005.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Final Office Action, Mar. 2, 2006.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Response to Final Office Action, Jun. 2, 2006.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Advisory Action, Jun. 9, 2006.
U.S. Appl. No. 10/335,394, Kwak et al., filed Dec. 31, 2002, Communication RE; Appeal/Notice of Abandonement, Apr. 26, 2007.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Preliminary Amendment, Mar. 17, 2003.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Restriction Requirement, Jun. 15, 2004.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Restriction Requirement, Jul. 28, 2004.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Non-Final Office Action, Oct. 19, 2004.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Non-Final Office Action, Feb. 22, 2005.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Final Office Action, Dec. 14, 2005.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Interview Summary, Dec. 22, 2005.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Final Office Action, May 15, 2006.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Non-Final Office Action, Aug. 8, 2006.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Non-Final Office Action, Dec. 7, 2006.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Final Office Action, Mar. 8, 2007.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Final Office Action and Request for Continued Examination, Sep. 10, 2007.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Final Office Action, Nov. 28, 2007.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Final Office Action, Apr. 15, 2008.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Advisory Action, Apr. 29, 2008.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Request for Continued Examination, May 28, 2008.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Non-Final Office Action, Aug. 19, 2008.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Non-Final Office Action, Nov. 19, 2008.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Final Office Action, Feb. 13, 2009.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Final Office Action, Apr. 13, 2009.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Interview Summary, Apr. 16, 2009.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Advisory Action, May 13, 2009.
U.S. Appl. No. 10/380,927, Kwak et al., filed Mar. 17, 2003, Response to Final Office Action and Request for Continued Examination, Jun. 15, 2009.
PCT/US99/05345, filed Mar. 12, 1999, Kwak et al., Application with International Search Report, Jul. 15, 1999.
PCT/US01/29075, filed Sep. 17, 2001, Kwak et al., International Search Report, Sep. 25, 2002.
PCT/US01/29075, filed Sep. 17, 2001, Kwak et al., International Preliminary Examination Report, Sep. 15, 2004.
Biragyn et al., “B-Cell Malignancies as a Model for Cancer Vaccines: From Prototype Protein to Next Generation Genetic Chemokine Fusions,”Immunological Reviews, Munksgaard, vol. 170, Aug. 1999, pp. 115-126.
Biragyn et al., “Genetic Fusion of Chemokines to a Self Tumor Antigen Induces Protective, T-Cell Dependent Antitumor Immunity-”Nature Biotechnology, Nature Publishing, U.S., vol. 17, No. 3, Mar. 1, 1999, pp. 253-258.
Agrawal et al. Cell-cycle kinetics and VSV-G pseudotyped retrovirus-mediated gene transfer in blood-derived CD34+cells.Exp. Hematol. 24:738-747 (1996).
Alvarez et al. A phase I st

Affiliated with

Also associated with

Rating

Defensin-antigen fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Defensin-antigen fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defensin-antigen fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4316269